Author

D. Dibitetto

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 3 Approach:experimental assay· 3 Assay:DNA methylation· 2 Research Focus:drug response / drug discovery· 2 Assay:proteomics· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1

Frequent Co-Authors

M. B. Smolka· 2 shared M. Lopes· 2 shared A. A. Sartori· 1 shared A. Duarte· 1 shared A. N. Kousholt· 1 shared A. Sanchi· 1 shared C. F. R. Ascencao· 1 shared C. S. Sorensen· 1 shared

Activity by Year

2020-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 22 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

M. B. Smolka

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

H2AX promotes replication fork degradation and chemosensitivity in BRCA-deficient tumours

D. Dibitetto, M. Liptay, F. Vivalda, E. Gogola, H. Dogan, M. G. Fernandez, A. Duarte, J. A. Schmid, S. T. Durant, J. V. Forment, I. Klebic, M. Siffert, R. de Brujin, A. N. Kousholt, N. A. Marti, , S. Rottenberg

This study identifies H2AX's role in promoting replication fork degradation and chemosensitivity in BRCA-deficient tumours, independent of its classical DNA damage signalling function.

bioRxiv · May 22, 2023Cancer Biology

Fork Slowing and Reversal as an Adaptive Response to Chronic ATR Inhibition

D. Dibitetto, A. Sanchi, E. J. Sanford, M. Lopes, M. B. Smolka

This study investigates the effects of chronic low-dose ATR inhibition on replication dynamics, revealing fork reversal as an adaptive response that enhances cell survival and can be exploited to improve cancer therapies.

bioRxiv · May 18, 2021 · PreprintCancer Biology

ATR Inhibitors as Potent Modulators of DNA End Resection Capacity

D. Dibitetto, J. R. Sims, C. F. R. Ascencao, K. Feng, R. Freire, M. B. Smolka

This study shows that long-term ATR inhibition reduces DNA end resection and DNA repair efficiency in cancer cells, offering a strategy to enhance PARP inhibitor sensitivity.

bioRxiv · Jan 13, 2020 · PreprintCancer Biology